Sea Pharmaceuticals Announces Strategic Relationship to Advance Treatments For Patients with CNS Disorders [Yahoo! Finance]
Inotiv, Inc. (NOTV)
Company Research
Source: Yahoo! Finance
Sea's lead molecule SPM-0404 is a potential new oral treatment in investigational new drug (IND)-enabling studies for constant bothersome tinnitus, epilepsy, and sporadic ALS (S-ALS) Pre-clinical development work by Inotiv, Inc. to support Sea filing IND application at FDA Inotiv Inc will assist Sea to quantify SPM-0404 levels in Clinical Phase 1 and Ph.1b Trials CAMBRIDGE, MA / ACCESS Newswire / April 6, 2025 / Sea Pharmaceuticals, LLC (Sea) today announced its selection of Inotiv Inc. (NASDAQ:NOTV) for pre-clinical development IND-enabling studies to support the advancement of Sea's lead molecule SPM-0404 as a potential new oral medicine to treat tinnitus, epilepsy and S-ALS. Sea's SPM-0404 and a second-generation molecule SPM-0606 represent a portfolio strategy of discovery and development of potent, selective, CNS-penetrant molecules targeting excitatory glutamate neurotransmission. A 100% Sea-owned patent estate protects Sea's novel chemical composition of matter in separa
Show less
Read more
Impact Snapshot
Event Time:
NOTV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NOTV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NOTV alerts
High impacting Inotiv, Inc. news events
Weekly update
A roundup of the hottest topics
NOTV
News
- Inotiv Partners with VUGENE to Advance AI-Driven Drug Discovery and Bioinformatics Capabilities [Yahoo! Finance]Yahoo! Finance
- Inotiv Partners with VUGENE to Advance AI-Driven Drug Discovery and Bioinformatics CapabilitiesGlobeNewswire
- Inotiv Inc (NOTV) Q4 2025 Earnings Call Highlights: Revenue Growth Amid Cybersecurity Challenges [Yahoo! Finance]Yahoo! Finance
- Inotiv (NASDAQ:NOTV) had its "buy" rating reaffirmed by analysts at Lake Street Capital.MarketBeat
- Inotiv, Inc. (NOTV) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
NOTV
Earnings
- 8/6/25 - Miss
NOTV
Sec Filings
- 12/5/25 - Form 10-K
- 12/3/25 - Form 8-K
- 12/2/25 - Form 4
- NOTV's page on the SEC website